TIFFANY WALLER: Open Payments
NPI 1275082430 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,681 in 144 payments from 18 companies in 2025. Trend: 2023 $2,833 · 2024 $2,135 · 2025 $2,681
Food & beverage: $2,569Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $491 |
| Otsuka America Pharmaceutical, Inc. | 12 | $266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $246 |
| Supernus Pharmaceuticals, Inc. | 15 | $244 |
| Teva Pharmaceuticals USA, Inc. | 12 | $241 |
| Neurocrine BioSciences, Inc. | 8 | $197 |
| ABBVIE INC. | 25 | $195 |
| Corium, LLC | 8 | $184 |
| Lundbeck LLC | 5 | $123 |
| Janssen Pharmaceuticals, Inc | 5 | $105 |
Products named: CAPLYTA, REXULTI, TRINTELLIX, Qelbree, INGREZZA, VRAYLAR, Azstarys, ABILIFY MAINTENA.
Industry payments across AL — which companies pay providers there.
